← FDA DRUG APPROVALS

FDA ANDA · ANDA214609

VENLAFAXINE

Sponsor: SOMERSET THERAPS LLC

APPLICATION
ANDA214609
TYPE
ANDA
ORIGINAL APPROVAL
2021-06-30
LATEST ACTION
2024-04-09
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 225MG BASE · TABLET, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2024-04-09Labeling · Supplement 2 · standardAP
2021-06-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →